Founded in 1997, Ergomed Group is a global provider of specialized clinical research, drug development, and pharmacovigilance services to the pharmaceutical and biotechnology industries. The company operates primarily through three specialized divisions: Ergomed Clinical Research (a full-service Contract Research Organization focusing on oncology, rare diseases, and complex trials), PrimeVigilance (offering industry-leading, end-to-end pharmacovigilance and medical information services), and ADAMAS Consulting (providing comprehensive GxP quality assurance audits and regulatory compliance). With a presence in over 100 countries, Ergomed supports its clients through every stage of the product lifecycle, from early-phase clinical development to post-marketing surveillance. In 2023, the company was acquired by the global private equity firm Permira.
